Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
- Indications Atherosclerosis; Cardiovascular disorders; Hyperlipidaemia; Myocardial infarction; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms FOURIER; PROFICIO
- Sponsors Amgen
- 13 Nov 2023 Results from FOURIER and FOURIER OLE assessing Long-Term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease, presented at the American Heart Association Scientific Sessions 2023
- 10 Nov 2023 Results presented in the Amgen Media Release
- 10 Nov 2023 According to an Amgen media release, data from the study were presented at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia.